본문 바로가기
KERD
논문KCI 등재

Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery

Disha Kesharwani|Rishi Paliwal|Trilochan Satapathy|Swarnali Das Paul
대한약침학회 (Korean Pharmacopuncture Institute)|2019.12|Journal of Pharmacopuncture|제22권 제4호|pp. 210-224|DOI https://doi.org/10.3831/KPI.2019.22.029

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

CytokinesArthritisrituximabDisease-modifying anti-rheumatic drugsTNF- α Interleukinsabataceptglucocorticoid.
주제분류한의학

초록

Rheumatoid arthritis is a severe autoimmune disorder, related to joints. It is associated with serious cartilage destruction. This causes disability and reduces the excellence of life. Numerous treatments are existed to combat this disease, however, they are not very efficient and possess severe side effects, higher doses, and frequent administration. Therefore, newer therapies are developed to overcome all these limitations. These include different monoclonal antibodies, immunoglobulins, small molecules used for immunotherapy and transgenes for gene therapy. One of the main goals of these new generation therapeutics is to address the underlying distressing biological processes by specifically targeting the causative agents with fewer systemic side effects and greater patient console. It is very fortuitous that loads of progressive investigations are going on in this field and many of them have entered into the successful clinical trial. But till date, a limited molecule has got FDA clearance and entered the market for treating this devastating disease. This review highlights the overview of conventional therapy and advancements in newer therapeutics including immunotherapy and gene therapy for rheumatoid arthritis. Further, different novel techniques for the delivery of these therapeutics of active and passive targeting are also described.

Abstract

Rheumatoid arthritis is a severe autoimmune disorder, related to joints. It is associated with serious cartilage destruction. This causes disability and reduces the excellence of life. Numerous treatments are existed to combat this disease, however, they are not very efficient and possess severe side effects, higher doses, and frequent administration. Therefore, newer therapies are developed to overcome all these limitations. These include different monoclonal antibodies, immunoglobulins, small molecules used for immunotherapy and transgenes for gene therapy. One of the main goals of these new generation therapeutics is to address the underlying distressing biological processes by specifically targeting the causative agents with fewer systemic side effects and greater patient console. It is very fortuitous that loads of progressive investigations are going on in this field and many of them have entered into the successful clinical trial. But till date, a limited molecule has got FDA clearance and entered the market for treating this devastating disease. This review highlights the overview of conventional therapy and advancements in newer therapeutics including immunotherapy and gene therapy for rheumatoid arthritis. Further, different novel techniques for the delivery of these therapeutics of active and passive targeting are also described.

참고문헌 (92)

  1. Klareskog L, "Mechanisms of disease : genetic susceptibility and environmental triggers in the development of rheumatoid arthritis", Nat Clin Pract Rheumatol, 2(8), pp.425~433 (2006)
  2. Lawrence T, "Transcriptional regulation of Macrophage polarization : Enabling diversity with identity", Nat Rev Immunol, 11(11), pp.750~761 (2011)
  3. Firestein GS, "Evolving Concepts of Rheumatoid Arthritis", Nature, 423(6937), pp.356~361 (2003)
  4. Ferrari M, "Going with the flow : harnessing the power of the vasculature for targeted therapy in rheumatoid arthritis", Drug Discovery Today, 21(1), pp.172~179 (2016)
  5. Wright HL, "The multifactorial role of neutrophils in rheumatoid arthritis", Nat Rev Rheumatol, 10, pp.593~601 (2014)
  6. Koenders MI, "Novel therapeutic targets in rheumatoid arthritis", Trends Pharmacol Sci, 36, pp.189~195 (2015)
  7. Helmick CG, "Estimates of the prevalence of arthritis and other rheumatic conditions in the United States : part I", Arthritis Rheum, 58, pp.15~25 (2008)
  8. William DA, "Non-steroidal anti-inflammatory drug. Foye's Medicinal Chemistry", pp.751~793 (2006), Williams and Wilkins
  9. Clària J., "Cyclooxygenase-2 Biology", Current Pharmaceutical Design, 9(27), pp.2177~2190 (2003)
  10. Ribbens C, "Increased synovial fluid levels of interleukin-12, sCD25, and sTNF-RII", sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies, 2000, pp.11(4), 669~676
  11. Yang L, "The effect of sodium hyaluronate treating knee osteoarthritis on synovial fluid interleukin-1β and clinical treat¬ment mechanism", Pak J Pharm Sci, 28(1), pp.407~410 (2015)
  12. Moura CC, "Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application", Int J Nanomed, 9, pp.4911~ (2014)[DOI]
  13. Mashaghi S, "Lipid nanotechnology", Int J Mol Sci, 14, pp.4242~4282 (2013)
  14. Sehgal R., "Nanotechnology and its applications in drug delivery. A review", Int J Mol Med, 3, pp.267~ (2013)
  15. Coco R, "Drug delivery to the inflamed colon by nanoparticles : Comparison of different strategies", Int J Pharm, 440, pp.3~12 (2013)
  16. Schnitzer TJ, "The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis", Clinical Therapeutics, 21(10), pp.1688~1702 (1999)
  17. Krug HLK, "Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis", Clinical Therapeutics, 22(1), pp.40~52 (2000)
  18. Hoes JN, "Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis", Nat Rev Rheumatol, 6(12), pp.693~702 (2010)
  19. Buttgereit F, "Targeting pathophysiological rhythms : prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis", Ann Rheum Dis, 69(7), pp.1275~1280 (2010)
  20. Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs", Ann Rheum Dis, 69(6), pp.964~975 (2010)
  21. McConkey B, "Sulphasalazine in rheumatoid arthritis", Br Med J, 280, pp.442~444 (1980)
  22. Verstappen SM, "A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up", Ann Rheum Dis, 64, pp.38~43 (2005)
  23. Quan LD, "The development of novel therapies for rheumatoid arthritis", Expert Opinion on Therapeutic Patents, 18(7), pp.723~738 (2008)
  24. Michael EW, "Methotrexate in Rheumatoid Arthritis : A Quarter Century of Development", Trans Am Clin Climatol Assoc, 124, pp.16~25 (2013)
  25. Maccagno A, "Effectiveness of etodolac(‘Lodine’)compared with naproxen in patients with acute gout", Current medical research and opinion, 12(7), pp.423~429 (1991)
  26. Weaver A, "Improved gastrointestinal tolerance and patient preference of enteric-coated sulfasalazine versus uncoated sulfasalazine tablets in patients with rheumatoid arthritis", Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 5(4), pp.193~200 (1999)
  27. Gaston G, "A double-blind, randomized, parallel-group study of the pharmacokinetics and onset of action of Naprelan in patients following oral surgery", American journal of orthopedics(Belle Mead, NJ), 25(9), pp.37~41 (1996)
  28. Altman R, "Advances in NSAID development : evolution of diclofenac products using pharmaceutical technology", Indian Drugs, 75(8), pp.859~877 (2015)
  29. Peyman G.A., "MINU LLC. Enhanced wound healing", U.S. Patent Application 12, 2008, pp.182~
  30. Prakash A, "Leflunomide", Indian Drugs, 58(6), pp.1137~1164 (1999)
  31. Graul AI, "The year’s new drugs", Drug News Perspect, 16, pp.22~39 (2003)
  32. Sibbald B, "Rofecoxib(Vioxx)voluntarily withdrawn from the market", Canadian Medical Association Journal, 171(9), pp.1027~1028 (2004)
  33. Miner JrP, "Clinical trial : evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400(naproxen", esomeprazole magnesium)compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg : a randomized, open-label, Phase I study in healthy volunteers, 2010, pp.32(3), 414~424
  34. Bello AE, "DUEXIS®(ibuprofen 800 mg, famotidine 26.6 mg: a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug", Therapeutic advances in musculoskeletal disease, 4(5), pp.327~339 (2012)
  35. Choy EH, "Anti-CD4 monoclonal antibodies in rheumatoid arthritis", Springer Semin Immunopathol, 20, pp.261~273 (1998)
  36. St Clair WE, "Combination of infliximab and methotrexate therapy for early rheumatoid arthritis : A randomized, controlled trial", Arthritis Rheum, 50, pp.3432~3443 (2004)
  37. David SP, "Advances in the Treatment of Rheumatoid ArthritisCosts and Challenges", North Carolina Medical Journal, 78(5), pp.337~340 (2017)
  38. Tanaka T, "Monoclonal antibodies in rheumatoid arthritis : comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors", Biologics : targets & therapy, 8, pp.141~ (2014)
  39. Yamada A, "The role of novel T cell costimulatory pathways in autoimmunity and transplantation", Journal of the American Society of Nephrology, 13(2), pp.559~575 (2002)
  40. Ogale S, "Patterns of biologic agent utilization among patients with rheumatoid arthritis : a retrospective cohort study", BMC musculoskeletal disorders, 12(1), pp.204~ (2002)
  41. Chakraborty A, "Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody", Clinical pharmacokinetics, 51(6), pp.1~18 (2012)
  42. Khan MM, "Monoclonal Antibodies as Therapeutic Agents", pp.157~196 (2016), Immunopharmacology Springer
  43. Campbell L, "Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab : a systematic literature review and meta-analysis of randomized controlled trials", Rheumatology, 50(3), pp.552~562 (2010)
  44. Hanada T, "Regulation of cytokine signaling and inflammation", Cytokine & growth factor reviews, 13(4-5), pp.413~421 (2002)
  45. Robbins PD, "Gene therapy for arthritis", Gene Therapy, 10(10), pp.902~ (2003)
  46. Evans CH, "Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-Arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania", Human gene therapy, 7(10), pp.1261~1280 (1996)
  47. Baugh JA, "A functional promoter polymorphism in the macrophage migration inhibitory factor(MIF)gene associated with disease severity in rheumatoid arthritis", Genes and immunity, 3(3), pp.170~ (2002)
  48. Kim JM, "Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist", Gene therapy, 10(18), pp.1543~ (2003)
  49. Woods JM, "Gene therapy for rheumatoid arthritis : recent advances", Current gene therapy, 8(1), pp.24~41 (2008)
  50. Campbell IK, "Granulocyte-macrophage colony-stimulating factor exacerbates collagen-induced arthritis in mice", Annals of the rheumatic diseases, 56(6), pp.364~368 (1997)
  51. Heslop HE, "Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes", Nature medicine, 2(5), pp.551~ (1996)
  52. Palmer G, "Interleukin-33 biology with potential insights into human diseases", Nature Reviews Rheumatology, 7(6), pp.321~ (2011)
  53. Wang H, "Adenovirus-Mediated Gene Transfer of Human Growth and Differentiation Factor-5 (GDF-5) into the Healing Rat Achilles Tendon", Molecular Therapy, 9(S1), pp.S336~ (2004)
  54. Evans CH, "Arthritis gene therapy and its tortuous path into the clinic", Translational Research, 161(4), pp.205~216 (2013)
  55. Goyal A, "Potential of novel drug delivery systems for herbal drugs", Ind J Pharm Educ Res, 45, pp.225~235 (2011)
  56. Lee SM, "Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles", ACS Nano, 7(1), pp.50~57 (2012)
  57. Albuquerque J, "Solid lipid nanoparticles : a potential multifunctional approach towards rheumatoid arthritis theranostics", Molecules, 20(6), pp.11103~11118 (2015)
  58. Lee SM, "Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles", ACS Nano, 7(1), pp.50~57 (2013)
  59. Satya PM, "A Review on Role of Nanoparticles in Rheumatoid arthritis therapy", Indian Journal of Research in Pharmacy and Biotechnology, 4(6), pp.255~ (2016)
  60. Lee H, "Hyaluronate–gold nanoparticle", tocilizumab complex for the treatment of rheumatoid arthritis, 2014, pp.8(5), 4790~4798
  61. Homma A, "Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment", Bioorganic & medicinal chemistry, 17(13), pp.4647~4656 (2009)
  62. Zheng Z, "The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats", Drug design, development, and therapy, 9, pp.4931~ (2015)
  63. Sailaja AK, "Formulation of Mefenamic Acid Loaded Polymeric Nanoparticles for the Treatment of Rheumatoid Arthritis", Journal of Bionanoscience, 12(2), pp.177~183 (2018)
  64. Zhou PH, "Chondroprotective Effects of Hyaluronic Acid-Chitosan Nanoparticles Containing Plasmid DNA Encoding Cytokine Response Modifier A in a Rat Knee Osteoarthritis Model", Cellular Physiology and Biochemistry, 47(3), pp.1207~1216 (2018)
  65. Fan W, "Intra-articular injection of kartogenin-conjugated polyurethane nanoparticles attenuates the progression of osteoarthritis", Drug delivery, 25(1), pp.1004~1012 (2018)
  66. Ye J, "Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis", International journal of pharmaceutics, 352(1-2), pp.273~279 (2008)
  67. Boechat AL, "Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model", International journal of nanomedicine, 10, pp.6603~ (2015)
  68. Zhou M, "Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy", Drug delivery, 25(1), pp.716~722 (2018)
  69. Metselaar JM, "Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis", Annals of the rheumatic diseases, 63(4), pp.348~353 (2004)
  70. Thulasiramaraju TV, "Liposome : A novel drug delivery system", International Journal of Biopharmaceutics, 3(1), pp.5~16 (2012)
  71. Williams AS, "Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant-induced arthritis", Clinical & Experimental Immunology, 102(3), pp.560~565 (1995)
  72. Metselaar J, "Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes", Arthritis & Rheumatology, 48(7), pp.2059~2066 (2003)
  73. Prabhu P, "Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity", International journal of nanomedicine, 7, pp.177~ (2012)
  74. Gottschalk O, "Therapeutic effect of methotrexate encapsulated in cationic liposomes(EndoMTX)in comparison to free methotrexate in an antigen-induced arthritis study in vivo", Scandinavian journal of rheumatology, 44(6), pp.456~463 (2015)
  75. Rahman M, "Nanomedicine-based drug targeting for psoriasis : potentials and emerging trends in nanoscale pharmacotherapy", Expert opinion on drug delivery, 12(4), pp.635~652 (2015)
  76. Jia M, "A novel dexamethasone-loaded liposome alleviates rheumatoid arthritis in rats", International journal of pharmaceutics, 540(1-2), pp.57~64 (2018)
  77. Tan C, "Exploring polymeric micelles for improved delivery of anticancer agents : recent developments in preclinical studies", Pharmaceutics, 5(1), pp.201~219 (2013)
  78. Ho KS, "Design considerations of polymeric nanoparticle micelles for chemotherapeutic delivery", Current Opinion in Chemical Engineering, 2(1), pp.53~59 (2013)
  79. Crielaard BJ, "Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis", Angewandte Chemie International Edition, 51(29), pp.254~258 (2012)
  80. Sethi V, "Novel, biocompatible, and disease-modifying VIP nanomedicine for rheumatoid arthritis", Molecular Pharmaceutics, 10(2), pp.728~738 (2013)
  81. Mason TG, "Nanoemulsions : formation, structure, and physical properties", J Phys: Condens Matter, 18, pp.R635~R666 (2006)
  82. Singh Y, "Nanoemulsion : Concepts, development, and applications in drug delivery", Journal of Controlled Release, 252, pp.28~49 (2017)
  83. Pey CM, "Optimization of nano-emulsions prepared by low-energy emulsification methods at a constant temperature using a factorial design study", Colloids and Surfaces A: Physicochemical and Engineering Aspects, 288(1-3), pp.144~150 (2006)
  84. Shakeel F, "Celecoxib nanoemulsion : skin permeation mechanism and bioavailability assessment", Journal of drug targeting, 16(10), pp.733~740 (2008)
  85. Mello SB, "Anti-inflammatory effects of intravenous methotrexate associated with lipid nanoemulsions on antigen-induced arthritis", Clinics, 71(1), pp.54~58 (2016)
  86. Modi JD, "Nanoemulsion-based gel formulation of aceclofenac for topical delivery", International Journal of Pharmacy and Pharmaceutical Science Research, 1(1), pp.6~12 (2011)
  87. Wani TU, "Targeting Aspects of Nanogels : An Overview", International Journal of Pharmaceutical Sciences and Nanotechnology, 7(4), pp.2612~2630 (2014)
  88. Chen W, "In situ forming reduction-sensitive degradable nanogels for facile loading and triggered the intracellular release of proteins", Biomacromolecules, 14(4), pp.1214~1222 (2013)
  89. Samah NA, "Nanogel particulates located within diffusion cell receptor phases following topical application demonstrates uptake into and migration across the skin", International journal of pharmaceutics, 401(1-2), pp.72~78 (2010)
  90. Nagai N, "Topical therapies for rheumatoid arthritis by gel ointments containing indomethacin nanoparticles in adjuvant-induced arthritis rat", Journal of oleo science, 64(3), pp.337~346 (2015)
  91. Khurana S, "Preparation and evaluation of solid lipid nanoparticles based nanogel for dermal delivery of meloxicam", Chemistry and physics of lipids, 175, pp.65~72 (2013)
  92. Elkomy MH, "Development of a nanogel formulation for transdermal delivery of tenoxicam : a pharmacokinetic-pharmacodynamic modeling approach for quantitative prediction of skin absorption", Drug development and industrial pharmacy, 43(4), pp.531~544 (2017)

관련 논문AI추천

Recent Paradigm Shifts in the Diagnosis and Treatment of Rheumatoid Arthritis김현아, 정영옥대한내과학회 · The Korean Journal of Internal Medicine2012 · 제27권 제4호Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research김민교, 이상일, 채용호대한면역학회 · Immune Network2022 · 제22권 제1호Current concepts in the management of rheumatoid arthritisYoshiya Tanaka대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제2호Current and Future Molecular Mechanism in Inflammation and ArthritisRaj Kumar Tiwari, Ravindra Kumar Pandey, Shiv Shankar Shukla, Vikash Sharma대한약침학회 · Journal of Pharmacopuncture2020 · 제23권 제2호류마티스관절염 치료지침 업데이트이주하대한내과학회 · 대한내과학회지2022 · 제97권 제2호Synovial Fluid as a Crucial Component of the Joint Microenvironment in Rheumatoid ArthritisAripova Tamara Uktamovna, Bjørklund Geir, Chirumbolo Salvatore, Gaffarov Usmon Bobonazarovich, Kamalov Zaynitdin Saifitdinovich, Khamidov Obid Abdurakhmanovich, Khudaiberdiev Shavkat Shukhratovich, Rizaev Jasur Alimdjanovich, Tashkenbaeva Eleonora Negmatovna, Ziyadullaev Shukhrat Khudaiberdievich대한면역학회 · Immune Network2025 · 제25권 제2호

이 간행물의 다른 논문 (9건)

Efficacy of Chamomile in the Treatment of Premenstrual Syndrome: A Systematic ReviewMahshid Bokaie, Soheila Pirdadeh Beiranvand, Zahra Bostani Khalesipp. 204-209A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC육태한, 김종욱, 김경한, 양진원, 김석희pp. 225-230An In Vitro and In Vivo Cholinesterase Inhibitory Activity of Pistacia khinjuk and Allium sativum Essential OilsAshraf Hajhoseini, Motahare-Sadat Hosseini, Anoosheh Sharifan, Peyman Ghajarbeygipp. 231-238Allium Jesdianum Extract Improve AcetaminophenInduced Hepatic Failure through Inhibition of Oxidative/Nitrosative StressAmir Nili-Ahmadabadi, Zohreh Sohrabinezhad, Dara Dastan, Sara Soleimani Aslpp. 239-247Urtica Dioica and Lamium Album Decrease Glycogen Synthase Kinase-3 beta and Increase K-Ras in Diabetic RatsKorosh Khanaki, Tahere Pourmirzaee, Mohammad Rostampour, Mahmood Abedinzade, Zahra Bostani Khalesi, Ebrahim Mirzajanipp. 248-252
원문 보기